ARTICLE | Company News
Merck, Sumitomo deal
July 11, 2005 7:00 AM UTC
Sumito granted MRK an exclusive worldwide license to develop and commercialize its SM-13496 lurasidone antipsychotic. The deal excludes Japan, China, Korea and Taiwan. The dopamine D2 receptor and ...